CEREBROLYSIN 10ml

Trade name: CEREBROLYSIN

Country: Austria

Quantity and Release Form: 10ml x 5 Ampoules

Active ingredient: cerebrolysin-neurotrophic peptides comp.

Medicinal form: solution for injection.

Composition:
Active substance: 1 ml of aqueous solution of the drug contains 215.2 mg of Cerebrolysin concentrate (a complex of peptides obtained from the brain of a pig). The active fraction of Cerebrolysin is represented by peptides with a molecular weight of not more than 10,000 Daltons.

Excipients: sodium hydroxide and water for injection.

Description
Amber-colored transparent solution, free from mechanical inclusions.

Pharmaceutical group
Nootropic agent
Pharmacological action

Pharmacodynamics

Cerebrolysin contains low-molecular biologically active neuropeptides that penetrate the blood-brain barrier and are directly delivered to nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. it provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

a) Metabolic regulation: Cerebrolysin increases the activity of aerobic energy metabolism in the brain, improves intracellular protein synthesis in the developing and aging brain.
b) Neutroprotection: Cerebrolysin protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases their viability and prevents the death of neurons under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).
c) Neurotropic activity: Cerebrolysin is the only nootropic peptidergic drug that has neurotrophic activity similar to natural neuronal growth factors (NGF), which is manifested under conditions of peripheral administration.
d) Functional neuromodulation: Cerebrolysin has a positive effect on cognitive function and memory processes.

Pharmacokinetics

The complex composition of Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with a total polyfunctional effect, prevents the usual pharmacokinetic analysis of individual components.

Indications for use

Alzheimer's disease, dementia syndrome of various genesis, chronic cerebrovascular insufficiency, ischemic stroke, traumatic brain and spinal cord injuries associated with attention deficit in children; in complex therapy - endogenous depression resistant to antidepressants.

Contraindications

Individual intolerance to the drug
Acute renal failure
Status epilepticus

Pregnancy and lactation

The drug is prescribed with caution in the first trimester of pregnancy and during lactation.

During pregnancy and lactation, Cerebrolysin can be used only after analyzing the ratio of the positive effect of treatment and the associated risk. The results of experimental studies do not provide grounds to assume whether Cerebrolysin has any effect or whether it has a toxic effect on the fetus. However, such clinical studies have not been conducted.

Directions for use and dosage

Adopted parenterally. Dosage and duration of treatment depend on the nature and severity of the disease, as well as the patient's age. Single doses of up to 50 ml may be administered, but it is best to complete the entire course of treatment.

The recommended optimal course of treatment is daily injections for 10-12 days.

To increase the effectiveness of treatment, repeated courses of treatment may be carried out until the patient's condition improves as a result of treatment. After the first course, the frequency of doses prescribed can be reduced to 2-3 weeks.

Cerebrolysin is used in the form of injections: intramuscularly (up to 5 ml) and intravenously (up to 10 ml). Doses from 10 to 50 ml are recommended to be administered only by slow intravenous infusion, after dilution in a standard infusion solution. The duration of infusion is 15-60 minutes.

Conditions of release: Out of prescription.